Skip to main content

Advertisement

SpringerLink
Log in

Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Objective

To evaluate prognostic factors associated with local control and disease-free-survival (DFS) of oligometastatic breast cancer patients treated by percutaneous thermal ablation (PTA).

Materials and Methods

Seventy-nine consecutive patients (54.5 ± 11.2 years old) with 114 breast cancer metastases (28.9 ± 16.1 mm in diameter), involving the lungs, the liver, and/or the bone, were treated using PTA with a curative intent. The goal was to achieve a complete remission in association with systemic chemotherapy and hormonal therapy. We retrospectively evaluated the prognostic factors associated with 1- and 2-year local control and the 1- and 2-year DFS rates.

Results

The 1- and 2-year local control rates were 83.0 and 76.1 %, respectively. Tumor burden was associated with a poorer outcome for local control after PTA (HR 1.027 by additional millimeter, p = 0.026; >4 cm HR 3.90). The 1- and 2-year DFS rates were 54.2 and 30.4 %, respectively. In multivariate analysis, triple-negative histological subtype and increased size of treated metastases were associated with a poorer DFS (HR 2.22; 95 % CI [1.13–4.36]; p = 0.02 and HR 2.43; 95 % CI [1.22–4.82]; p = 0.011, respectively).

Conclusion

PTA is effective for local control of breast cancer oligometastases. Tumor burden >4 cm and triple-negative histological subtype are associated with a poorer outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

PTA:

Percutaneous thermal ablation

DFS:

Disease-free survival

CT:

Computed tomography

MRI:

Magnetic resonance imaging

FDG-PET:

Fluoro-deoxy-glucose positron emission tomography

OS:

Overall survival

References

  1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–89.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;2009:225–49.

    Article  Google Scholar 

  3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.

    Article  CAS  PubMed  Google Scholar 

  4. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;12(384):164–72.

    Article  Google Scholar 

  5. Holmes FA, Buzdar AU, Kau S-W, et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED)—the M. D. Anderson experience. Breast Dis. 1994;7:7–20.

    Google Scholar 

  6. Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist. 2003;8:241–51.

    Article  PubMed  Google Scholar 

  7. Bathe OF, Kaklamanos IG, Moffat FL, Boggs J, Franceschi D, Livingstone AS. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol. 1999;8:35–42.

    Article  CAS  PubMed  Google Scholar 

  8. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–91.

    Article  PubMed  Google Scholar 

  9. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86:336–42.

    Article  PubMed  Google Scholar 

  10. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;1(83):878–86.

    Article  Google Scholar 

  11. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220:145–9.

    Article  CAS  PubMed  Google Scholar 

  12. Lawes D, Chopada A, Gillams A, Lees W, Taylor I. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl. 2006;88:639–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol. 2007;18:67–72.

    Article  PubMed  Google Scholar 

  14. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. Am J Roentgenol. 2007;189:883–9.

    Article  CAS  Google Scholar 

  15. Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee FT. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation intermediate and long-term survival rates. Radiology. 2009;253:861–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jakobs TF, Hoffmann RT, Schrader A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Interv Radiol. 2009;32:38–46.

    Article  Google Scholar 

  17. Palussière J, Dixmerias F, Buy X, et al. Interventional radiology procedures in the treatment of bone metastasis. Cancer. 2009;96:1117–26.

    Google Scholar 

  18. Gangi A, Buy X. Interventional radiology in lung cancer: from diagnosis to treatment. Rev Mal Respir. 2007;24(6):137–45.

    Article  Google Scholar 

  19. de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.

    Article  PubMed  Google Scholar 

  20. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

    CAS  PubMed  Google Scholar 

  21. Bergenfeldt M, Jensen BV, Skjoldbye B, Nielsen D. Liver resection and local ablation of breast cancer liver metastases. A systematic review. EJSO. 2011;37:549–57.

    Article  CAS  PubMed  Google Scholar 

  22. Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the international registry of lung metastases. J Thorac Oncol. 2011;6:1373–8.

    Article  PubMed  Google Scholar 

  23. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:28–37.

    Article  Google Scholar 

  24. Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6:369–74.

    PubMed  PubMed Central  Google Scholar 

  25. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.

    Article  PubMed  Google Scholar 

  26. Lermite E, Marzano E, Chéreau E, Rouzier R, Pessaux P. Surgical resection of liver metastases from breast cancer. Surg Oncol. 2010;19:79–84.

    Article  Google Scholar 

  27. Illing R, Gillams A. Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol. 2010;22:781–4.

    Article  CAS  Google Scholar 

  28. Gervais DA. Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? J Vasc Interv Radiol. 2013;24:1135–8.

    Article  PubMed  Google Scholar 

  29. Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015;40(1829–1837):35.

    Google Scholar 

  30. Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology. 2004;233:729–39.

    Article  PubMed  Google Scholar 

  31. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206–13.

    Article  CAS  PubMed  Google Scholar 

  32. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8.

    Article  PubMed  Google Scholar 

  33. Palussiere J, Lagarde P, Aupérin A, Deschamps F, Chomy F, de Baere T. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years’ experience in 87 patients from two centers. Cardiovasc Intervent Radiol. 2015;38:160–6.

    Article  PubMed  Google Scholar 

  34. Iguchi T, Hiraki T, Gobara H, et al. Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. Cardiovasc Intervent Radiol. 2015;38:409–15.

    Article  PubMed  Google Scholar 

  35. Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 2015;38:135–42.

    Article  PubMed  Google Scholar 

  36. Koelblinger C, Strauss S, Gillams A. Outcome after radiofrequency ablation of sarcoma lung metastases. Cardiovasc Intervent Radiol. 2014;37:147–53.

    Article  PubMed  Google Scholar 

  37. Deschamps F, Farouil G, Ternes N, et al. Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol. 2014;24:1971–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Radiology Department, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805, Villejuif, France

    M. Barral, A. Hakime, V. Cartier, V. Tacher, L. Tselikas, T. de Baere & F. Deschamps

  2. Biostatistics and Epidemiology Unit, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805, Villejuif, France

    A. Auperin

  3. Radiotherapy, Centre Clinique de la Porte de Saint-Cloud, 37 avenue Victor Hugo, 92100, Boulogne Billancourt, France

    Yves Otmezguine

Authors
  1. M. Barral
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Auperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Hakime
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Cartier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Tacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yves Otmezguine
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Tselikas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. de Baere
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Deschamps
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Barral.

Ethics declarations

Conflict of Interest

All authors of the manuscript: Barral Matthias, Aupérin Anne, Hakimé Antoine, Cartier Victoire, Tacher Vania, Otmezguine Yves, Tselikas Lambros, de Baere Thierry, and Deschamps Frédéric have nothing to disclose.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barral, M., Auperin, A., Hakime, A. et al. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients. Cardiovasc Intervent Radiol 39, 885–893 (2016). https://doi.org/10.1007/s00270-016-1301-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-016-1301-x

Keywords

Search

Navigation